SEC Form 4 · accession 0001127602-18-010592
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · CRL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James C Foster
Officer — Chairman & CEO · Director
Period of report
Mar 6, 2018
Accepted (ET)
Mar 7, 2018 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2018 | M | 24,008 | $88.05 | A | 325,684 | D | |
| Common Stock | Mar 6, 2018 | S | 24,008 | $110.00 | D | 301,676 | D | |
| Common Stock | holding | — | — | — | 10,208 | I | 2016 GRAT | |
| Common Stock | holding | — | — | — | 29,954 | I | 2017 GRAT | |
| Common Stock | holding | — | — | — | 340 | I | By Trust | |
| Common Stock | holding | — | — | — | 10,000 | I | Held By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $88.05 | Mar 6, 2018 | M | 24,008 | D | Feb 24, 2018 | Feb 24, 2022 | Common Stock | 24,008 | 72,025 | D |
Explanation of responses
- F1This sale occurred pursuant to a 10b5-1 Trading Plan.